Karin Fijnvandraat

Professor
Emma Kinderziekenhuis/AMC, University of Amsterdam, Netherlands
Amsterdam, Noord-Holland, Netherlands

Presentation(s):

• PB0281 - Baseline coagulation factor levels determine desmopressin response in bleeding disorders: a systematic review and meta-analysis

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0278 - Current practice regarding Bleeding Disorder of Unknown Cause (BDUC) in the Netherlands: a national survey

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0285 - Diagnosing and treating Bleeding Disorder of Unknown Cause: an illustrated review on current practice and future directions

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0280 - Patient perspective of the burden and severity of von Willebrand disease

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0274 - Re-establishing von Willebrand Factor production in endothelial cells derived from von Willebrand Disease type 3 canine models through CRISPR-Cas9 mediated gene editing

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0525 - Real-world Bleeding Rates on Emicizumab using Digital Treatment Diary data

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0634 - The MAPTO survey, Mapping Approaches to Tolerance in PUP/MTP treatment around the world in the non-replacement era

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• OC 50.2 - Long-term outcomes with efanesoctocog alfa prophylaxis for previously treated children with severe hemophilia A, an interim analysis of the phase 3 XTEND-ed study

  Tuesday, June 25, 2024
  09:45 – 10:00 ICT

• OC 61.2 - Determinants of successful immune tolerance induction in people with severe hemophilia A

  Tuesday, June 25, 2024
  15:00 – 15:15 ICT